


FIGURE S1 LEGEND

Figure S1. PRISMA flow diagram of the bibliographic systematic review



SUPPLEMENTARY MATERIAL FOR THE ARTICLE

WHAT IS KNOWN ON ANGIOGENESIS-RELATED RARE DISEASES? A SYSTEMATIC REVIEW OF LITERATURE

Luis Rodríguez-Caso¹, Armando Reyes-Palomares¹, Francisca Sánchez-Jiménez^{1,2}, Ana R. Quesada^{1,2} and Miguel Ángel Medina^{1,2}

¹Departamento de Biología Molecular y Bioquímica, Facultad de Ciencias, Universidad de Málaga, E-29071 Málaga, and ²CIBER de Enfermedades Raras (CIBERER), Málaga, SPAIN

CONTENTS OF THE SUPPLEMENTARY MATERIAL

*References (the whole set of selected bibliographic references related to the 187 angiogenic rare diseases covered by this work)

*Figure S1 legend

*Figure S1

*Tables S1 to S10

SUPPLEMENTARY REFERENCES

(The whole set of selected bibliographic references related to the 187 angiogenic rare diseases covered by this work)

1. **Abedalthagafi M, Rushing E, Auerbach A, et al.** Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases. *Ann Diagn Pathol.* 2010; 14: 15-22.
2. **Adam Z, Krikavova L, Krejci M, et al.** Treatment of multiple angiomatosis involving the skeleton and the abdominal and thoracic cavities with interferon alpha, thalidomide and zoledronate. *Vnitřní lékařství.* 2008; 54: 653-64.
3. **Adamis AP, Aiello LP, D'Amato RA.** Angiogenesis and ophthalmic disease. *Angiogenesis.* 1999; 3: 9-14.
4. **Akakin A, Ozkan A, Akgun E, et al.** Endovascular treatment increases but gamma knife radiosurgery decreases angiogenic activity of arteriovenous malformations: an in vivo experimental study using a rat cornea model. *Neurosurgery.* 2010; 66: 121-9; discussion 9-30.
5. **Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC.** Eruptive tufted angiomas in a patient with Crohn's disease. *Journal of Clinical Pathology.* 2005; 58: 214-6.
6. **Alizadeh AA, Advani RH.** Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. *Clinical advances in hematology & oncology : H&O.* 2008; 6: 899-909.
7. **Andrieux J, Roche-Lestienne C, Geffroy S, et al.** Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis. *Cancer Genetics and Cytogenetics.* 2007; 178: 11-6.
8. **Aoki Y, Tosato G.** Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. *Blood.* 1999; 94: 4247-54.
9. **Are C, Shaha AR.** Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches. *Annals of Surgical Oncology.* 2006; 13: 453-64.
10. **Arrabal-Polo MA, Arias-Santiago SA, Aneiros-Fernandez J, et al.** Cutaneous metastases in renal cell carcinoma: a case report. *Cases journal.* 2009; 2: 7948.
11. **Assaad AM, Kawut SM, Arcasoy SM, et al.** Platelet-derived growth factor is increased in pulmonary capillary hemangiomatosis. *Chest.* 2007; 131: 850-5.

12. **Aust G, Krohn K, Morgenthaler NG, et al.** Graves' disease and Hashimoto's thyroiditis in monozygotic twins: case study as well as transcriptomic and immunohistological analysis of thyroid tissues. *European Journal of Endocrinology*. 2006; 154: 13-20.
13. **Baccin CE, Krings T, Alvarez H, Ozanne A, Lasjaunias PL.** A report of two cases with dolichosegmental intracranial arteries as a new feature of PHACES syndrome. *Childs Nervous System*. 2007; 23: 559-67.
14. **Bacher G, Bevec D, Cavalli F, Cavalli V.** New peptide useful e.g. for treating/preventing systemic sclerosis, multiple sclerosis, Sjogren's disease, vascular malformations in blood and lymph vessels, hereditary hemorrhagic telangiectasia and cavernous hemangioma. Mondobiotech Lab Ag, 2009.
15. **Bacher G, Bevec D, Cavalli F, et al.** New peptide, useful in medicine e.g. to treat and/or prevent cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases and heart- and vascular diseases. Mondobiotech Lab Ag; Bevec D; Cavalli F, 2009.
16. **Baker LH, Rowinsky EK, Mendelson D, et al.** Randomized, Phase II Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Soft Tissue Sarcoma. *Journal of Clinical Oncology*. 2008; 26: 5583-8.
17. **Barker KT, Foulkes WD, Schwartz CE, et al.** Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? *Journal of Medical Genetics*. 2006; 43: 613-4.
18. **Bellastella A, Bizzarro A, Coronella C, et al.** Lymphocytic hypophysitis: a rare or underestimated disease? *European Journal of Endocrinology*. 2003; 149: 363-76.
19. **Bisacchi D, Noonan DM, Carlone S, et al.** Kaposi sarcoma and human chorionic gonadotropin: Mechanisms, moieties and mysteries. *Biological Chemistry*. 2002; 383: 1315-20.
20. **Bodner A, Pelte MF, Verbist MC, Dietrich PY.** New treatments for renal cell carcinoma: hope and limits. *Revue medicale suisse*. 2007; 3: 1290-4.
21. **Boshoff C, Weiss RA.** Kaposi's sarcoma-associated herpesvirus. *Advances in Cancer Research, Vol 75*. 1998; 75: 57-86.
22. **Bradley DA, Dunn R, Nanus D, et al.** Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design. *Clinical Genitourinary Cancer*. 2007; 5: 460-3.

23. **Bressler NM.** Antiangiogenic Approaches to Age-Related Macular Degeneration Today. *Ophthalmology*. 2009; 116: S15-S23.
24. **Buttin BM, Moore MJ.** Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer. *Gynecologic Oncology*. 2008; 111: 546-8.
25. **Calabro L, Di Giacomo AM, Altomonte M, et al.** Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: Is there room for novel anti-angiogenetic treatments? *Journal of Experimental & Clinical Cancer Research*. 2007; 26: 145-50.
26. **Capurso G, Fazio N, Festa S, et al.** Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. *Critical Reviews in Oncology Hematology*. 2009; 72: 110-24.
27. **Casas-Ganem J, Healey JH.** Advances that are changing the diagnosis and treatment of malignant bone tumors. *Current Opinion in Rheumatology*. 2005; 17: 79-85.
28. **Cassier PA, Dufresne A, El Sayadi H, et al.** Targeted therapy of sarcomas. *Bulletin Du Cancer*. 2008; 95: 963-74.
29. **Cassier PA, Dufresne A, Fayette J, et al.** Emerging drugs for the treatment of soft tissue sarcomas. *Expert Opinion on Emerging Drugs*. 2007; 12: 139-53.
30. **Chinen K, Kazumoto T, Ohkura Y, et al.** Pulmonary tumor thrombotic microangiopathy caused by a gastric carcinoma expressing vascular endothelial growth factor and tissue factor. *Pathology International*. 2005; 55: 27-31.
31. **Ciufo DM, Cannon JS, Poole LJ, et al.** Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: Formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures. *Journal of Virology*. 2001; 75: 5614-26.
32. **Clark TE, Edom N, Larson J, Lindsey LJ.** Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. *Drug Safety*. 2001; 24: 87-117.
33. **Colucci S, Taraboletti G, Primo L, et al.** Gorham-Stout syndrome: A monocyte-mediated cytokine propelled disease. *Journal of Bone and Mineral Research*. 2006; 21: 207-18.
34. **Daliani DD, Papandreou CN, Thall PF, et al.** A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. *Cancer*. 2002; 95: 758-65.

35. **Davidson B, Dong HP, Holth A, et al.** The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. *Breast Journal*. 2008; 14: 476-82.
36. **de Lima AS, Martynychen MG, Florencio RT, et al.** Pulmonary lymphangiomatosis: a report of two cases. *Jornal brasileiro de pneumologia : publicação oficial da Sociedade Brasileira de Pneumologia e Tisiologia*. 2007; 33: 229-33.
37. **Dignat-George F, Sampol J, Lip G, Blann AD.** Circulating endothelial cells: Realities and promises in vascular disorders. *Pathophysiology of Haemostasis and Thrombosis*. 2003; 33: 495-9.
38. **Dupond JL, Bermont L, Runge M, de Billy M.** Plasma VEGF determination in disseminated lymphangiomatosis-Gorham-Stout syndrome: A marker of activity? A case report with a 5-year follow-up. *Bone*. 2010; 46: 873-6.
39. **Einwallner E, Ahlers C, Golbaz I, et al.** Neovascular age-related macular degeneration under anti-angiogenic therapy. *Ophthalmologie*. 2010; 107: 158-64.
40. **Ensoli B, Sirianni MC.** Kaposi's sarcoma pathogenesis: A link between immunology and tumor biology. *Critical Reviews in Oncogenesis*. 1998; 9: 107-24.
41. **Ensoli B, Sturzl M, Monini P.** Cytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. *Seminars in Cancer Biology*. 2000; 10: 367-81.
42. **Escudier B, Eisen T, Stadler WM, et al.** Sorafenib in advanced clear-cell renal-cell carcinoma. *New England Journal of Medicine*. 2007; 356: 125-34.
43. **Fan C, Ouyang P, Timur AA, et al.** Novel Roles of GATA1 in Regulation of Angiogenic Factor AGGF1 and Endothelial Cell Function. *Journal of Biological Chemistry*. 2009; 284: 23331-43.
44. **Fang AM, Lee AY, Kulkarni M, et al.** Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. *Molecular Vision*. 2009; 15: 2710-9.
45. **Feiz-Erfan I, Zabramski JM, Herrmann LL, Coons SW.** Cavernous malformation within a schwannoma: review of the literature and hypothesis of a common genetic etiology. *Acta Neurochirurgica*. 2006; 148: 647-52.
46. **Filippi S, Latini P, Frontini M, et al.** CSB protein is (a direct target of HIF-1 and) a critical mediator of the hypoxic response. *Embo Journal*. 2008; 27: 2545-56.

47. **Freeman D, Lesche R, Kertesz N, et al.** Genetic background controls tumor development in Pten-deficient mice. *Cancer Research*. 2006; 66: 6492-6.
48. **Fury MG, Zahalsky A, Wong R, et al.** A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. *Investigational New Drugs*. 2007; 25: 165-72.
49. **Gan GG, Pasagna JFJ, Eow GI, Nadarajan VS.** Chronic neutrophilic leukaemia. *Singapore medical journal*. 2007; 48: e74-6.
50. **Gault J, Sarin H, Awadallah NA, et al.** Pathobiology of human cerebrovascular malformations: Basic mechanisms and clinical relevance. *Neurosurgery*. 2004; 55: 1-16.
51. **Gesundheit B, Parkin P, Greenberg M, et al.** The Role of Angiogenesis in the Transformation of Plexiform Neurofibroma into Malignant Peripheral Nerve Sheath Tumors in Children With Neurofibromatosis Type 1. *Journal of Pediatric Hematology Oncology*. 2010; 32: 548-53.
52. **Gimenez-Roqueplo A-P.** New advances in the genetics of pheochromocytoma and paraganglioma syndromes. *Pheochromocytoma*. 2006; 1073: 112-21.
53. **Giins LC, Roberts DH, Mark EJ, et al.** Pulmonary capillary hemangiomatosis with atypical endotheliomatosis - Successful antiangiogenic therapy with doxycycline. *Chest*. 2003; 124: 2017-22.
54. **Glasgow CG, Steagall WK, Taveira-DaSilva A, et al.** Lymphangiomyomatosis (LAM): Molecular insights lead to targeted therapies. *Respiratory Medicine*. 2010; 104: S45-S58.
55. **Goodman VL, Brewer GJ, Merajver SD.** Copper deficiency as an anti-cancer strategy. *Endocrine-Related Cancer*. 2004; 11: 255-63.
56. **Goodman VL, Brewer GJ, Merajver SD.** Control of copper status for cancer therapy. *Current Cancer Drug Targets*. 2005; 5: 543-9.
57. **Goon PKY, Lip GYH, Boos CJ, Stonelake PS, Blann AD.** Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. *Neoplasia*. 2006; 8: 79-88.
58. **Goss G, Demetri G.** Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. *Surgical Oncology-Oxford*. 2000; 9: 53-9.
59. **Greco M, D'Alo F, Scardocci A, et al.** Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.

Blood Cells Molecules and Diseases. 2010; 45: 181-5.

60. **Grotzinger C.** Tumour biology of gastroenteropancreatic neuroendocrine tumours. *Neuroendocrinology*. 2004; 80 Suppl 1: 8-11.
61. **Gudena V, Verma N, Post G, et al.** Metastatic chest wall malignant schwannoma responding to sorafenib - Case report and literature review. *Cancer Biology & Therapy*. 2008; 7: 810-3.
62. **Gulino AV.** WHIM syndrome: a genetic disorder of leukocyte trafficking. *Current opinion in allergy and clinical immunology*. 2003; 3: 443-50.
63. **Gutterman JU.** Cytokine therapeutics: lessons from interferon-alpha. *Proceedings of the National Academy of Sciences of the United States of America*. 1994; 91: 1198-205.
64. **Halter F, Wildersmith CH.** Gastrin: friend or foe of peptic-ulcer. *Journal of Clinical Gastroenterology*. 1991; 13: S75-S82.
65. **Hamada T, McLean WHI, Ramsay M, et al.** Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). *Human Molecular Genetics*. 2002; 11: 833-40.
66. **Han X, Zhou D-B.** Advances in etiology and management of Castleman's disease. *Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae*. 2009; 31: 639-43.
67. **Han Z, Wu K, Shen H, Li C, Han S, et al.** Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation. *Digestive Diseases and Sciences*. 2008; 53: 1801-10.
68. **Harrison MR, Huang W, Liu G, Gee J.** Response to Antiangiogenesis Therapy in a Patient With Advanced Adult-Type Testicular Granulosa Cell Tumor. *Oncology-New York*. 2009; 23: 792-5.
69. **Heffelfinger SC, Yassin RW, Miller MA, Lower EE.** Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breast pathologies: Correlation with vascularity. *Pathobiology*. 2000; 68: 129-36.
70. **Heldwein FL, Escudier B, Smyth G, et al.** Metastatic Renal Cell Carcinoma Management. *International Braz J Urol*. 2009; 35: 256-70.
71. **Heritier S, Le Merrer M, Jaubert F, et al.** Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009. *Orphanet Journal of Rare Diseases*. 2010; 5.
72. **Hirohata S, Kikuchi H.** Histopathology of the ruptured pulmonary artery

aneurysm in a patient with Behcet's disease. *Clinical and Experimental Rheumatology*. 2009; 27: S91-S5.

73. **Hulkova H, Poupetova H, Harzer K, et al.** Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries. *Journal of Inherited Metabolic Disease*. 2010; 33: 69-78.

74. **Humbert M.** Mutations of genes coding for TGF-beta receptors (BMP2 and ALK-1) in primary pulmonary arterial hypertension. *Journal de la Societe de biologie*. 2002; 196: 53-8.

75. **Ieremia G, Raica M, Cimpean AM, Bocan V.** Morphologic and histochemical changes in the skin of patients with scleroderma. *Romanian journal of morphology and embryology*. 2007; 48: 361-7.

76. **Iison DH.** Oesophageal cancer: new developments in systemic therapy. *Cancer Treatment Reviews*. 2003; 29: 525-32.

77. **Iison DH.** New developments in the treatment of esophageal cancer. *Clinical advances in hematology & oncology : H&O*. 2004; 2: 97-104.

78. **Inoue R, Nakazawa A, Tsukada N, et al.** POEMS syndrome with idiopathic portal hypertension: Autopsy case and review of the literature. *Pathology International*. 2010; 60: 316-20.

79. **Joshi D, James A, Quaglia A, et al.** Liver disease in pregnancy. *Lancet*. 2010; 375: 594-605.

80. **Joussen AM, Kirchhof B.** Solitary peripapillary hemangioblastoma - A histopathological case report. *Acta Ophthalmologica Scandinavica*. 2001; 79: 83-7.

81. **Kaplan MH.** Human retroviruses and neoplastic disease. *Clinical Infectious Diseases*. 1993; 17: S400-S6.

82. **Karkkainen MJ, Ferrell RE, Lawrence EC, et al.** Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. *Nature Genetics*. 2000; 25: 153-9.

83. **Kasper B, Ho AD, Egerer G.** A new therapeutic approach in patients with advanced sarcoma. *International journal of clinical oncology / Japan Society of Clinical Oncology*. 2005; 10: 438-40.

84. **Kassam A, Mandel K.** Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl. *Journal of Pediatric Hematology Oncology*. 2008; 30: 550-2.

85. **Kastritis E, Murray S, Kyriakou F, et al.** Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt

pathway implication. *International Journal of Cancer*. 2009; 124: 103-8.

86. **Kawamoto A, Katayama M, Handa N, et al.** Intramuscular Transplantation of G-CSF-Mobilized CD34(+) Cells in Patients With Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single-Blinded, Dose-Escalation Clinical Trial. *Stem Cells*. 2009; 27: 2857-64.
87. **Kawamura N, Kira J-I.** Treatment strategy for POEMS syndrome. *Brain and nerve = Shinkei kenkyu no shinpo*. 2008; 60: 621-6.
88. **Kenemans P, Verstraeten RA, Verheijen RHM.** Oncogenic pathways in hereditary and sporadic breast cancer. *Maturitas*. 2004; 49: 34-43.
89. **Killory BD, Gonzalez LF, Wait SD, et al.** Simultaneous unilateral moyamoya disease and ipsilateral dural arteriovenous fistula: case report. *Neurosurgery*. 2008; 62: E1375-E6.
90. **Kirsch M, Allende R, Black P, Schackert G.** Endogenous growth inhibition of angiogenesis in brain tumors. *Cancer and Metastasis Reviews*. 2007; 26: 469-79.
91. **Kudo M.** Atypical large well-differentiated hepatocellular carcinoma with benign nature: A new clinical entity. *Intervirolgy*. 2004; 47: 227-37.
92. **Kuivanen T, Tanskanen M, Jahkola T, et al.** Matrilysin-1 (MMP-7) and MMP-19 are expressed by Paget's cells in extramammary Paget's disease. *Journal of Cutaneous Pathology*. 2004; 31: 483-91.
93. **Lenato GM, Guanti G.** Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and molecular aspects. *Current Pharmaceutical Design*. 2006; 12: 1173-93.
94. **Lenato GM, Suppressa P, Giordano P, et al.** Hereditary haemorrhagic telangiectasia: A rare disease as a model for the study of human atherosclerosis. *Current Pharmaceutical Design*. 2007; 13: 3656-64.
95. **Lentrodts S, Lentrodts J, Kubler N, Modder U.** Hyperbaric oxygen for adjuvant therapy for chronically recurrent mandibular osteomyelitis in childhood and adolescence. *Journal of Oral and Maxillofacial Surgery*. 2007; 65: 186-91.
96. **Lerebours F, Vacher S, Andrieu C, et al.** NF-kappa B genes have a major role in Inflammatory Breast Cancer. *Bmc Cancer*. 2008; 8.
97. **Li X, Gao Z-J, Cao J-W, Yu B-P, et al.** Increase of mast cells may be associated with infiltration of eosinophils and proliferation of microvessels in gastric eosinophilic granuloma. *Journal of Gastroenterology and Hepatology*. 2007; 22: 37-42.

98. **Limaye N, Wouters V, Uebelhoer M, et al.** Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. *Nature Genetics*. 2009; 41: 118-24.
99. **Limaye N, Boon LM, Vikkula M.** From germline towards somatic mutations in the pathophysiology of vascular anomalies. *Human Molecular Genetics*. 2009; 18: R65-R74.
100. **Linnankivi T, Valanne L, Paetau A, et al.** Cerebroretinal microangiopathy with calcifications and cysts. *Neurology*. 2006; 67: 1437-43.
101. **Los M, Aarsman CJM, Terpstra L, et al.** Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. *Annals of Oncology*. 1997; 8: 1015-22.
102. **Lukiw WJ, Gordon WC, Rogaev EI, et al.** Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis. *Neuroreport*. 2001; 12: 53-7.
103. **Mascarenhas RCV, Sanghvi AN, Friedlander L, et al.** Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. *Oncology*. 2004; 67: 471-5.
104. **Mason JO III, White MF, Feist RM, et al.** Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. *Retina-the Journal of Retinal and Vitreous Diseases*. 2008; 28: 564-7.
105. **Masuda Y, Shimizu A, Mori T, et al.** Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. *American Journal of Pathology*. 2001; 159: 599-608.
106. **Mattes D, Haas A, Renner W, et al.** Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration. *Molecular Vision*. 2009; 15: 343-8.
107. **Maxwell PH.** Oxygen homeostasis and cancer: insights from a rare disease. *Clinical Medicine*. 2002; 2: 356-62.
108. **Maynard MA, Ohh M.** Molecular targets from VHL studies into the oxygen-sensing pathway. *Current Cancer Drug Targets*. 2005; 5: 345-56.
109. **McAllister SC, Moses AV.** Endothelial cell- and lymphocyte-based in vitro systems for understanding KSHV biology. *Kaposi Sarcoma Herpesvirus: New Perspectives*. 2007; 312: 211-44.
110. **Medina J, Garcia-Buey L, Moreno-Otero R.** Immunopathogenetic and therapeutic aspects of autoimmune hepatitis. *Alimentary Pharmacology &*

Therapeutics. 2003; 17: 1-16.

111. **Melgarejo E, Angel Medina M, Sanchez-Jimenez F, Luis Urdiales J.** Targeting of histamine producing cells by EGCG: a green dart against inflammation? *Journal of Physiology and Biochemistry*. 2010; 66: 265-70.
112. **Mennel S, Barbazetto I, Meyer CH, et al.** Ocular photodynamic therapy - Standard applications and new indications (part 2). *Ophthalmologica*. 2007; 221: 282-91.
113. **Mitsuyama H, Matsuyama W, Iwakawa J, et al.** Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome. *Chest*. 2006; 129: 407-11.
114. **Mohamed AO, Kamar N, Nogier M-B, et al.** Tamoxifen Therapy in Kidney-Transplant Patients Presenting With Severe Encapsulating Peritoneal Sclerosis After Treatment for Acute Humoral Rejection. *Experimental and Clinical Transplantation*. 2009; 7: 164-7.
115. **Moriatis JM, Gannon FH, Shore EM, et al.** Limb swelling in patients who have fibrodysplasia ossificans progressiva. *Clinical Orthopaedics and Related Research*. 1997: 247-53.
116. **Mulamalla K, Truskinovsky AM, Dudek AZ.** Rare case of hemangiopericytoma responds to sunitinib. *Translational Research*. 2008; 151: 129-33.
117. **Nagel S, Busch C, Blankenburg T, Schutte W.** Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab. *Pneumologie (Stuttgart, Germany)*. 2009; 63: 387-9.
118. **O'Byrne KJ, Schally AV, Thomas A, et al.** Somatostatin, its receptors and analogs, in lung cancer. *Chemotherapy*. 2001; 47: 78-108.
119. **O'Cearbhaill R, Hensley ML.** Optimal management of uterine leiomyosarcoma. *Expert Review of Anticancer Therapy*. 2010; 10: 153-69.
120. **Odrzywolski KJ, Mukhopadhyay S.** Papillary Cystadenoma of the Epididymis. *Archives of Pathology & Laboratory Medicine*. 2010; 134: 630-3.
121. **Ojeda-Fernandez L, Barrios L, Rodriguez-Barbero A, et al.** Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT). *Clinica Chimica Acta*. 2010; 411: 494-9.
122. **Okolo S.** Incidence, aetiology and epidemiology of uterine fibroids. *Best Practice & Research in Clinical Obstetrics & Gynaecology*. 2008; 22: 571-88.

123. **Olin JW, Shih A.** Thromboangiitis obliterans (Buerger's disease). *Current Opinion in Rheumatology*. 2006; 18: 18-24.
124. **Oudard S, Cassar A, Mejean A, et al.** Creation of a coordinating unit for the management of rare renal tumours in adult patients. *Oncologie*. 2008; 10: 437-42.
125. **Pagnucco G, Cardinale G, Gervasi F.** Targeting multiple myeloma cells and their bone marrow microenvironment. *Signal Transduction and Communication in Cancer Cells*. 2004; 1028: 390-9.
126. **Paik PK, Krug LM.** Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma Preclinical Rationale and Clinical Trials. *Journal of Thoracic Oncology*. 2010; 5: 275-9.
127. **Palestro G, Turrini F, Pagano M, Chiusa L.** Castleman's disease. *Advances in clinical pathology : the official journal of Adriatic Society of Pathology*. 1999; 3: 11-22.
128. **Papadopoulos KP, Thomas CR.** Current chemotherapy options for thymic epithelial neoplasms. *Expert Opinion on Pharmacotherapy*. 2005; 6: 1169-77.
129. **Paris D, Ait-Ghezala G, Mathura VS, et al.** Anti-angiogenic activity of the mutant Dutch A beta peptide on human brain microvascular endothelial cells. *Molecular Brain Research*. 2005; 136: 212-30.
130. **Paubel A, Violette J, Amy M, et al.** Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosis. *Archives of Neurology*. 2008; 65: 1333-6.
131. **Pelengaris S, Khan M.** Oncogenic co-operation in beta-cell tumorigenesis. *Endocrine-Related Cancer*. 2001; 8: 307-14.
132. **Rao CV, Reddy BS.** NSAIDs and chemoprevention. *Current Cancer Drug Targets*. 2004; 4: 29-42.
133. **Reis JS, Palva ME, Lopes JM.** Congenital composite hemangioendothelioma: case report and reappraisal of the hemangioendothelioma spectrum. *Journal of Cutaneous Pathology*. 2002; 29: 226-31.
134. **Reuwer AQ, Reuwer P, van der Post JA, et al.** Prolactin fragmentation by trophoblastic matrix metalloproteinases as a possible contributor to peripartum cardiomyopathy and pre-eclampsia. *Medical Hypotheses*. 2010; 74: 348-52.
135. **Richard S, Ladroue C, Gad S, et al.** Genetics and angiogenesis: the example of von Hippel-Lindau disease. *Bulletin Du Cancer*. 2007; 94: S170-S9.

136. **Riveiro-Alvarez R, Trujillo-Tiebas MJ, Gimenez-Pardo A, et al.** Genotype-phenotype variations in five spanish families with norrie disease or X-linked FEVR. *Molecular Vision*. 2005; 11: 705-12.
137. **Robinson J, Nye E, Stamp G, Silver A.** Osteogenic tumours in Lkb1-deficient mice. *Experimental and Molecular Pathology*. 2008; 85: 223-6.
138. **Robitaille JM, Wallace K, Zheng B, et al.** Phenotypic Overlap of Familial Exudative Vitreoretinopathy (FEVR) with Persistent Fetal Vasculature (PFV) Caused by FZD4 Mutations in two Distinct Pedigrees. *Ophthalmic Genetics*. 2009; 30: 23-30.
139. **Rubel IF, Carrer A, Gilles JJ, et al.** Progressive Gorham disease of the forearm. *Orthopedics*. 2008; 31: 284.
140. **Rudraiah L, Dhar G, Thatai D.** Acquired coronary cameral fistula - A report of two cases. *International Journal of Cardiology*. 2008; 123: E40-E2.
141. **Rullier A, Senant N, Kisiel W, et al.** Expression of protease-activated receptors and tissue factor in human liver. *Virchows Archiv*. 2006; 448: 46-51.
142. **Sanada S, Ookawara S, Karube H, Shindo T, Goto T, Nakamichi T, Saito M, Matsubara M, Suzuki M.** Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. *American Journal of Kidney Diseases*. 2006; 47: 672-9.
143. **Santos SNMBd, Oliveira GVd, Tavares ALP, et al.** Collagen XVIII and fibronectin involvement in bullous scleroderma. *Dermatology online journal*. 2005; 11: 17.
144. **Scala S, Ierano C, Ottaiano A, et al.** CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. *Cancer Immunology Immunotherapy*. 2007; 56: 1589-95.
145. **Scavelli C, Nico B, Cirulli T, et al.** Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. *Oncogene*. 2008; 27: 663-74.
146. **Scholz T, Eisenhofer G, Pacak K, et al.** Current treatment of malignant pheochromocytoma. *Journal of Clinical Endocrinology & Metabolism*. 2007; 92: 1217-25.
147. **Schteingart DE, Doherty GM, Gauger PG, et al.** Management of patients with adrenal cancer: recommendations of an international consensus conference. *Endocrine-Related Cancer*. 2005; 12: 667-80.
148. **Seiz M, Kohlhof P, Brockmann MA, et al.** First Experiences with Low-

dose Anti-angiogenic Treatment in Gliomatosis Cerebri with Signs of Angiogenic Activity. *Anticancer Research*. 2009; 29: 3261-7.

149. **Senechal B, Elain G, Jeziorski E, et al.** Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. *Plos Medicine*. 2007; 4: 1374-84.

150. **Serrao R, Zirwas M, English JC.** Palmar erythema. *American Journal of Clinical Dermatology*. 2007; 8: 347-56.

151. **Shah PK, Narendran V, Tawansy KA, et al.** Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. *Indian journal of ophthalmology*. 2007; 55: 75-6.

152. **Singhal S, Mehta J, Desikan R, et al.** Antitumor activity of thalidomide in refractory multiple myeloma. *New England Journal of Medicine*. 1999; 341: 1565-71.

153. **Soderberg-Naucler C.** Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? *Journal of Internal Medicine*. 2006; 259: 219-46.

154. **Soni S, Lee DS, DiVito J, et al.** Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. *Journal of Pediatric Hematology Oncology*. 2002; 24: 488-91.

155. **Sosman J, Puzanov I.** Combination Targeted Therapy in Advanced Renal Cell Carcinoma. *Cancer*. 2009; 115: 2368-75.

156. **Srikanth M, Davies FE, Wu P, et al.** Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. *European Journal of Haematology*. 2008; 81: 432-6.

157. **Srikanth SG, Nagarajan K, Chandrashekar HS, et al.** Unilateral moyamoya phenomenon due to MCA occlusion in a child presenting with intracerebral Hemorrhage. *Interventional Neuroradiology*. 2006; 12: 369-73.

158. **Stahler M, Haseke N, Schoppler G, et al.** Carcinoma of the collectin ducts of bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with Sunitinib. *European Journal of Medical Research*. 2008; 13: 531-5.

159. **Staudt MR, Kanan Y, Jeong JH, et al.** The tumor microenvironment controls primary effusion lymphoma growth in vivo. *Cancer Research*. 2004; 64: 4790-9.

160. **Stec R, Bodnar L, Smoter M, Szczylik C.** Bevacizumab plus irinotecan in treatment of recurrent brain gliomas. *Wspolczesna Onkologia-Contemporary Oncology*. 2010; 14: 253-8.

161. **Stockwin LH, Vistica DT, Kenney S, et al.** Gene expression profiling of alveolar soft-part sarcoma (ASPS). *Bmc Cancer*. 2009; 9.
162. **Stone RM, O'Donnell MR, Sekeres MA.** Acute myeloid leukemia. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program*. 2004: 98-117.
163. **Strupp C, Germing U, Scherer A, et al.** Thalidomide for the treatment of idiopathic myelofibrosis. *European Journal of Haematology*. 2004; 72: 52-7.
164. **Su H, Kim H, Pawlikowska L, et al.** Reduced Expression of Integrin alpha v beta 8 Is Associated with Brain Arteriovenous Malformation Pathogenesis. *American Journal of Pathology*. 2010; 176: 1018-27.
165. **Sueblinvong V, Weiss DJ.** Stem cells and cell therapy approaches in lung biology and diseases. *Translational Research*. 2010; 156: 188-205.
166. **Suzuki OT, Sertie AL, Der Kaloustian VM, et al.** Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndrome. *American Journal of Human Genetics*. 2002; 71: 1320-9.
167. **Taraseviciute A, Voelkel NF.** Severe pulmonary hypertension in postmenopausal obese women. *European Journal of Medical Research*. 2006; 11: 198-202.
168. **Taveira-DaSilva AM, Steagall WK, Moss J.** Lymphangioliomyomatosis. *Cancer control : journal of the Moffitt Cancer Center*. 2006; 13: 276-85.
169. **Thomas S, Encha-Razavi F, Devisme L, et al.** High-Throughput Sequencing of a 4.1 Mb Linkage Interval Reveals FLVCR2 Deletions and Mutations in Lethal Cerebral Vasculopathy. *Human Mutation*. 2010; 31: 1134-41.
170. **Thun MJ, Henley SJ, Patrono C.** Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. *Journal of the National Cancer Institute*. 2002; 94: 252-66.
171. **Tolppanen A-M, Nevalainen T, Kolehmainen M, et al.** Single nucleotide polymorphisms of the tenomodulin gene (TNMD) in age-related macular degeneration. *Molecular Vision*. 2009; 15: 762-70.
172. **Tournier-Lasserre E.** Genetics of cerebral vascular accidents. *Archives Des Maladies Du Coeur Et Des Vaisseaux*. 2003; 96: 1105-10.
173. **Toyooka S, Kishimoto T, Date H.** Advances in the molecular biology of malignant mesothelioma. *Acta Medica Okayama*. 2008; 62: 1-7.

174. **Uchida T, Hayashi H, Inaoki M, et al.** A failure of mucocutaneous lymphangiogenesis may underlie the clinical features of lipoid proteinosis. *British Journal of Dermatology*. 2007; 156: 152-7.
175. **Uriu-Adams J, Scherr R, Lanoue L, Keen C.** Influence of copper on early development: prenatal and postnatal considerations. *Biofactors*. 2010; 36: 136-52.
176. **Vincenzi B, Frezza AM, Santini D, Tonini G.** New therapies in soft tissue sarcoma. *Expert Opinion on Emerging Drugs*. 2010; 15: 237-48.
177. **Ward S, Macgowan A, Roberts S, et al.** Use of derivatives of 18-beta glycyrrhetic acid for treatment or alleviation of the symptoms of a patient suffering from e.g. retinoid-sensitive disorder, psoriasis, acne vulgaris and cancer. York Pharma Plc; Ward S; Macgowan A, 2008.
178. **Wecke T, Knop C, Schreiber W, Behrens-Baumann W.** Intraocular injections of bevacizumab in rare indications - two cases. *Ophthalmologie*. 2009; 106: 435.
179. **Wells SA, Gosnell JE, Gagel RF, et al.** Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. *Journal of Clinical Oncology*. 2010; 28: 767-72.
180. **Williams AO, Banks PM, Liebelt AG, et al.** Angiofollicular lymphoid hyperplasia (Castelmans disease) in 2 mice treated with polyoma-virus or urethane. *Toxicologic Pathology*. 1993; 21: 26-34.
181. **Wong LJ, Desai RU, Jain A, et al.** Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. *Retina-the Journal of Retinal and Vitreous Diseases*. 2008; 28: 1151-8.
182. **Wu HK, Chen HL, Hu PC.** Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. *Clinical Laboratory*. 2007; 53: 285-95.
183. **Yamazaki K, Eyden B.** An immunohistochemical and ultrastructural study of pancreatic microcystic serous cyst adenoma with special reference to tumor-associated microvasculature and vascular endothelial growth factor in tumor cells. *Ultrastructural Pathology*. 2006; 30: 119-28.
184. **Zachary I.** Neuroprotective role of vascular endothelial growth factor: Signalling mechanisms, biological function, and therapeutic potential. *Neurosignals*. 2005; 14: 207-21.
185. **Zarrabeitia R, Albinana V, Salcedo M, et al.** A Review on Clinical

Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT). *Current Vascular Pharmacology*. 2010; 8: 473-81.

186. **Zhou Q, Zheng JW, Yang XJ, et al.** Fibronectin: Characterization of a somatic mutation in Sturge-Weber syndrome (SWS). *Medical Hypotheses*. 2009; 73: 199-200.

187. **Ziakas PD, Kopterides P, Voulgarelis M.** Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion. *Current Vascular Pharmacology*. 2010; 8: 51-8.